Core Insights - Bone Biologics Corporation achieved significant milestones in 2025, including the extension of rhNELL-1 shelf life, advancement of NB1 development, and a strengthened balance sheet while maintaining compliance with Nasdaq [1][2][5] 2025 Highlights - The company focused on strategic priorities across development, operations, and corporate governance to support ongoing programs and maintain organizational stability [3] - Key accomplishments included extending the validated shelf life of rhNELL-1 to 24 months, completing a public offering for gross proceeds of $5 million, and filing a U.S. patent application related to bone regeneration technology [5] - The company regained compliance with Nasdaq's minimum bid price requirement in June 2025, enhancing access to public capital markets [5] - Management increased investor engagement through participation in conferences and communication of progress in clinical and operational initiatives [5] Outlook for 2026 - The company plans to continue advancing its clinical-stage program and strengthening its operational foundation in 2026 [4] - Focus areas include the ongoing development of NB1, regulatory readiness, and commercialization planning [5] - The company aims to maintain prudent capital management while supporting scientific progress and shareholder engagement [5]

Registration Statement No. 333-276771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on February 23, 2024 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 42-1743430 (I.R.S. Employer ...